REG - Nuformix PLC - Result of AGM

NuformixAnnouncement

20/03/2025 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250320:nRST5163Ba&default-theme=true

RNS Number : 5163B  Nuformix PLC  20 March 2025

20 March 2025

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that
the Annual General Meeting ("AGM") of Nuformix plc was held earlier today and
all resolutions put to shareholders were duly passed by a show of hands.  The
proxy votes received were as follows:

 

     Resolution                                                          Ordinary/Special  For                  Against             Total votes cast
                                                                                           No. of votes  %      No. of votes  %     No. of votes
 1   To receive the Company's annual report and accounts                 Ordinary          88,884,205    99.5   449,137       0.5   89,333,342
 2   To approve the Directors' Remuneration Policy                       Ordinary          87,134,389    98.05  1,732,136     1.95  88,866,525
 3   To approve the remuneration report                                  Ordinary          87,134,389    98.07  1,712,636     1.93  88,847,025
 4   That Dr Daniel Gooding be re-appointed as a Director                Ordinary          88,672,332    99.51  433,313       0.49  89,105,645
 5   That Dr Julian Gilbert be re-appointed as a Director                Ordinary          88,632,832    99.49  453,313       0.51  89,086,145
 6   That Ms Madeleine Kennedy be re-appointed as a Director             Ordinary          88,620,969    99.50  441,479       0.50  89,062,448
 7   To re-appoint Kreston Reeves LLP as auditor of the Company          Ordinary          88,819,667    99.60  352,795       0.40  89,172,462
 8   To authorise the Directors to determine the auditor's remuneration  Ordinary          87,612,217    98.51  1,321,125     1.49  88,933,342
 9   To authorise the Directors to allot securities                      Ordinary          84,636,256    94.81  4,630,269     5.19  89,266,525
 10  To authorise the Directors to disapply pre-emption rights           Special           85,436,025    95.86  3,686,005     4.14  89,122,030
 11  To authorise the Company to purchase its own shares                 Special           87,796,808    98.88  992,039       1.12  88,788,847
 12  To authorise calling of a general meeting on 14 clear days' notice  Special           88,600,047    99.18  733,295       0.82  89,333,342

 

A vote withheld is not a vote in law and is not counted in the calculation of
votes validly cast for or against a resolution.

The Company's issued share capital is 1,669,309,368 ordinary shares of 0.05p
each.

Enquiries:

 

 Nuformix plc                            Via IFC Advisory

 Dr Daniel Gooding, Executive Director

 CMC Markets                             +44 (0) 20 3003 8632

 Douglas Crippen

 IFC Advisory Limited                    +44 (0) 20 3934 6630

 Tim Metcalfe                            nuformix@investor-focus.co.uk

 Zach Cohen

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

For more information, please visit www.nuformix.com (http://www.nuformix.com)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFBLFLEXLBBBK